单击此处进行编辑。Antibody can be regarded as a specific protein produced in response to counteract a unique antigen that is usually used to recognize and resist the invaders. It can combine chemically with the substances that the body recognizes as outsiders such as bacteria and viruses. Thus, people can reduce the levels of that special substance through introducing it into antibody. With the immune system, antibody can release a defensive protein, including molecular markers, for research of those destroyed diseased cells.
With the rapid development of antibody technology, single domain antibody can also accomplish the same task. Because its small body is accessible to the restricted area of macromolecules much easier, single domain antibody shows a more attractive prospect. However, there are still some difficulties remained to achieve the goal, since scientists haven’t found yet an effective method to identify this kind of antibody. Fortunately, this problem has been solved by researchers from Rockefeller University. They have developed a new successful technology which can ensure that single domain antibody will significantly meet the needs of massive researching fields. The key is to find a relatively quick way to determine the gene sequence of high-affinity single domain antibody, because once those sequences are obtained, it’s easy to conduct massive production of such antibodies utilizing bacteria. Researchers first inoculate GFP and mCherry for the llamas, helping their immune system to fight against antibody of the two foreign proteins and then extracting RNA from llamas’ antibody-producing cells for the purpose of establishing an antibody sequence database. After follow-up several procedures, the most high-affinity antibody can be paired with those original RNA sequences with the help of computer program named “llama magic”. Based on this new sequence, researchers have produced 25 kinds of single domain antibody that can precisely target GFP and six kinds at mCherry with a higher efficiency. This new sequence has aroused a new inspiration. Scientists can choose the most high-affinity single domain antibody and occasionally abandon those ungraded products, declining the required amount and reducing the side effects to a better degree. In short, modern nanobody technology is able to identify high-affinity single domain antibody. Comments are closed.
|
Archives
November 2016
Categories |